

Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Iron Sucrose
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Sandoz Launches Affordable Iron Sucrose Injection in US
Details : Venofer-Generic (iron sucrose) injection is indicated for the treatment of patients with chronic kidney disease.
Product Name : Venofer-Generic
Product Type : Vitamins/Minerals/Inorganic Salts
Upfront Cash : Inapplicable
September 24, 2025
Lead Product(s) : Iron Sucrose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Iron Sucrose
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S.
Details : Venofer (iron sucrose injection) is a brown, sterile, aqueous, complex of polynuclear iron (III)-hydroxide in sucrose for intravenous use.
Product Name : Venofer-Generic
Product Type : Carbohydrate
Upfront Cash : Inapplicable
August 11, 2025
Lead Product(s) : Iron Sucrose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Iron Sucrose
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amphastar Announces FDA Approval for Iron Sucrose Injection, USP
Details : Iron sucrose injection is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD).
Product Name : Venofer-Generic
Product Type : Carbohydrate
Upfront Cash : Inapplicable
August 11, 2025
Lead Product(s) : Iron Sucrose
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Renibus Completes Enrollment in Phase 3 PROTECT Trial of RBT-1 for Cardiac Surgery
Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, under evaluation to reduce post-operative complications.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 24, 2025
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Tolerability of 200mg and 100mg of Venofer Administered to Hemodialysis(HD) Patients
Details : Iron Sucrose is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
November 15, 2024
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Iron Sucrose Injection in Healthy Participants
Details : Iron Sucrose is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
November 05, 2024
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Iron Sucrose Injection in Healthy Subjects
Details : Iron Sucrose is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Carbohydrate
Upfront Cash : Inapplicable
October 01, 2024
Lead Product(s) : Iron Sucrose
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Henan (Zhengzhou) Zhonghui Cardiovascular Hospital | Changsha Duxact Biotechnology | Suzhou Guochen Biotechnology Co., Ltd.
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Renibus Announces Publication Of Results from Phase 2 Study Evaluating RBT-1
Details : RBT-1 (stannic protoporfin/iron sucrose), is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways, reduces post-op complications following cardiothoracic surgery.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 09, 2024
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory, antioxidant and iron-scavenging pathways currently in Phase 3 [NCT # 06021457] for its lead indication to reduce post-operative complications following cardiothoracic surg...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 25, 2023
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : $47.0 million
Deal Type : Series B Financing
Details : The proceeds will advance RBT-1 (stannic protoporfin/iron sucrose), a potent inducer of anti-inflammatory, antioxidant and iron scavenging pathways, through Phase 3 trial for reducing the risk of post-operative complications following cardiothoracic surg...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 18, 2023
Lead Product(s) : Stannic Protoporfin,Iron Sucrose
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : $47.0 million
Deal Type : Series B Financing
